wuwencan118@163.com
1988-1991 Loudi Health School, Hunan Province. Undergraduate
1998-2001 Weifang Medical University. Postgraduate
2001-2004 Central South University. Doctoral
2004.09-Present : Employed at the Eye Hospital of Wenzhou Medical University, with successive promotions to Lecturer/Attending Physician, Associate Professor/Associate Chief Physician, and Professor/Chief Physician. During this period:
2013.10-2015.08: Served as a Fellow at the Bascom Palmer Eye Institute in the United States, engaged in clinical diagnosis and treatment of orbital and oculoplastic diseases, as well as the development of animal models for traumatic optic nerve injury, research on the role of neural crest-derived stem cells in optic nerve injury repair, and the development of a miniature OCT system.
2009.04-2009.07: Completed advanced training in orbital/oculoplastic surgery and endoscopic sinus surgery at the Royal Adelaide Hospital in Australia.
2006.04-2006.07: Undertook training in endoscopic sinus surgery techniques at the First Affiliated Hospital of Sun Yat-sen University (Otolaryngology Hospital) in Guangzhou.
With over 20 years of dedication to clinical and basic research on optic nerve injury repair, he has pioneered a new interdisciplinary field of minimally invasive ophthalmic-rhinological surgery. He established the first minimally invasive interventional therapy system for optic nerve diseases, having performed over 8,000 ETOCD procedures—the highest number internationally. He proposed a new theory on the activation of residual optic nerve function and authored the Chinese Expert Consensus on Endoscopic Endonasal Optic Canal Decompression for Traumatic Optic Neuropathy and the leading work Minimally Invasive Ophthalmic-Rhinological Surgery (People's Medical Publishing House). By integrating medicine and engineering, and driving clinical and basic research synergistically, he addressed the critical challenge of optic nerve regeneration in TON by creating the first bionic large-animal TON model, developing nerve microconduits for directional axon regeneration (a key achievement of the 13th Five-Year Plan), pioneering key techniques for intrathecal microenvironment regulation and aptamer-targeted therapy, and inventing the world's only three-dimensional orbital surgical navigator and multispectral functional pupillometer.
His research interest include:
(1) Clinical Field:
Pioneered the internationally innovative discipline of minimally invasive ophthalmic-rhinological surgery, and was the first to apply endoscopic techniques to neuro-ophthalmology, oculoplastics, orbital diseases, and lacrimal disorders. He holds a globally leading position in the minimally invasive endoscopic treatment of optic nerve diseases, thyroid-associated ophthalmopathy, craniomaxillofacial fractures or tumors and deformities centered around the orbit, complex orbital tumors, and lacrimal diseases.
(2) Research Field:
① Mechanisms of optic nerve injury and regeneration, pathophysiological mechanisms of thyroid-associated ophthalmopathy, molecular mechanisms and targeted therapy of orbital tumors, and mechanisms of lacrimal mucosal injury and repair;② Development of medical devices and high-tech products for precise minimally invasive orbital surgery.
2005 Third Level, Zhejiang Province "New Century 151 Talent Project"
2010 International Endoscopic Distinguished Leadership Award
2012 Endoscopics Medical Science and Technology Award
2012 Second Level, Wenzhou City "551 Talent Project"
2013 Zhejiang Province Academic Leader for Mid-career and Young University Faculty
2017 Wenzhou Outstanding Talent
2018 Second Prize, National Teaching Achievement Award
2019 APAO Achievement Award
2021 5th "People's Renowned Doctor"
2021 Zhejiang Province Health Leadership Talent
2021 National Health Commission Outstanding Contribution Mid-career and Young Expert
2022 Wenzhou Top Ten Exemplary Workers with Craftsmanship Spirit
2023 Zhejiang Province "Ten Thousand Talents Plan" Distinguished Talent
2023 Zhejiang Province Young and Mid-career Expert with Outstanding Contributions
2023 First Prize, Zhejiang Provincial Science and Technology Progress Award
2025 First Prize, Outstanding Scientific Research Achievement Award (Engineering and Technology) of the Ministry of Education
1.Li H, Liu B, Lian L, Zhou J, Xiang S, Zhai Y, Chen Y, Ma X, Wu W, Hou L. High dose expression of heme oxigenase-1 induces retinal degeneration through ER stress-related DDIT3. Mol Neurodegener. 2021 Mar 10;16(1):16.
2.Xie T, Zhang Y, Ling N, Yuan Y, Liu W, Guo J, Wei X, Peng T, Wang Z, Dai J, Chen W, Yan M, Wu X, Wu W, Ye M, Tan W. Aptamer as a Molecular Tethering Agent Induces PrPC Aggregation and Degradation to Inhibit Melanoma Proliferation. Angew Chem Int Ed Engl. 2025 Jul 7;64(28):e202425051.
3.Li T, Zhang WM, Wang J, Liu BJ, Gao Q, Zhang J, Qian HD, Pan JY, Liu M, Huang Q, Fang AW, Zhang Q, Gong XH, Cui RZ, Liang YB, Lu QK, Wu WC, Chi ZL. Circulating Small Extracellular Vesicles Involved in Systemic Regulation Respond to RGC Degeneration in Glaucoma. Adv Sci (Weinh). 2024 Aug;11(32):e2309307.
4.Yu C, Zhou Y, Yao S, Wang Z, Ye S, Qi R, Hu H, Liu K, Wu Y, Lawson T, Yan L, Liu Y, Wu W. A Facile Strategy to Restore the Optic Nerve Functionality Using an Injectable Conducting Hydrogel. Adv Sci (Weinh). 2025 Jun;12(21):e2415601.
5.Zhang Y, Lu S, Huang S, Yu Z, Xia T, Li M, Yang C, Mao Y, Xu B, Wang L, Xu L, Shi J, Zhu X, Zhu S, Zhang S, Qian H, Hu Y, Li W, Tu Y, Wu W. Optic chiasmatic potential by endoscopically implanted skull base microinvasive biosensor: a brain-machine interface approach for anterior visual pathway assessment.Theranostics. 2022 Apr 11;12(7):3273-3287
6.Li K, Sun L, Wang Y, Cen Y, Zhao J, Liao Q, Wu W, Sun J, Zhou M. Single-cell characterization of macrophages in uveal melanoma uncovers transcriptionally heterogeneous subsets conferring poor prognosis and aggressive behavior. Exp Mol Med. 2023 Nov;55(11):2433-2444.
Chen H, Yan T, Song Z, Ying S, Wu B, Ju X, Yang X, Qu J, Wu W, Zhang Z, Wang Y. MD2 blockade prevents modified LDL-induced retinal injury in diabetes by suppressing NADPH oxidase-4 interaction with Toll-like receptor-4Exp Mol Med 2021 Apr;53(4):681-694
8.Wang L, Wang C, Tao Z, Zhao L, Zhu Z, Wu W, He Y, Chen H, Zheng B, Huang X, Yu Y, Yang L, Liang G, Cui R, Chen T. Curcumin derivative WZ35 inhibits tumor cell growth via ROS-YAP-JNK signaling pathway in breast cancer. J Exp Clin Cancer Res. 2019 Nov 8;38(1):460
